
Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

Your AI-Trained Oncology Knowledge Connection!


Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.

Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma.